Elevation of Intact and Proteolytic Fragments of Acute Phase Proteins Constitutes the Earliest Systemic Antiviral Response in HIV-1 Infection
The earliest immune responses activated in acute human immunodeficiency virus type 1 infection (AHI) exert a critical influence on subsequent virus spread or containment. During this time frame, components of the innate immune system such as macrophages and DCs, NK cells, β-defensins, complement and other anti-microbial factors, which have all been implicated in modulating HIV infection, may play particularly important roles. A proteomics-based screen was performed on a cohort from whom samples were available at time points prior to the earliest positive HIV detection. The ability of selected factors found to be elevated in the plasma during AHI to inhibit HIV-1 replication was analyzed using in vitro PBMC and DC infection models. Analysis of unique plasma donor panels spanning the eclipse and viral expansion phases revealed very early alterations in plasma proteins in AHI. Induction of acute phase protein serum amyloid A (A-SAA) occurred as early as 5–7 days prior to the first detection of plasma viral RNA, considerably prior to any elevation in systemic cytokine levels. Furthermore, a proteolytic fragment of alpha–1-antitrypsin (AAT), termed virus inhibitory peptide (VIRIP), was observed in plasma coincident with viremia. Both A-SAA and VIRIP have anti-viral activity in vitro and quantitation of their plasma levels indicated that circulating concentrations are likely to be within the range of their inhibitory activity. Our results provide evidence for a first wave of host anti-viral defense occurring in the eclipse phase of AHI prior to systemic activation of other immune responses. Insights gained into the mechanism of action of acute-phase reactants and other innate molecules against HIV and how they are induced could be exploited for the future development of more efficient prophylactic vaccine strategies.
Vyšlo v časopise:
Elevation of Intact and Proteolytic Fragments of Acute Phase Proteins Constitutes the Earliest Systemic Antiviral Response in HIV-1 Infection. PLoS Pathog 6(5): e32767. doi:10.1371/journal.ppat.1000893
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1000893
Souhrn
The earliest immune responses activated in acute human immunodeficiency virus type 1 infection (AHI) exert a critical influence on subsequent virus spread or containment. During this time frame, components of the innate immune system such as macrophages and DCs, NK cells, β-defensins, complement and other anti-microbial factors, which have all been implicated in modulating HIV infection, may play particularly important roles. A proteomics-based screen was performed on a cohort from whom samples were available at time points prior to the earliest positive HIV detection. The ability of selected factors found to be elevated in the plasma during AHI to inhibit HIV-1 replication was analyzed using in vitro PBMC and DC infection models. Analysis of unique plasma donor panels spanning the eclipse and viral expansion phases revealed very early alterations in plasma proteins in AHI. Induction of acute phase protein serum amyloid A (A-SAA) occurred as early as 5–7 days prior to the first detection of plasma viral RNA, considerably prior to any elevation in systemic cytokine levels. Furthermore, a proteolytic fragment of alpha–1-antitrypsin (AAT), termed virus inhibitory peptide (VIRIP), was observed in plasma coincident with viremia. Both A-SAA and VIRIP have anti-viral activity in vitro and quantitation of their plasma levels indicated that circulating concentrations are likely to be within the range of their inhibitory activity. Our results provide evidence for a first wave of host anti-viral defense occurring in the eclipse phase of AHI prior to systemic activation of other immune responses. Insights gained into the mechanism of action of acute-phase reactants and other innate molecules against HIV and how they are induced could be exploited for the future development of more efficient prophylactic vaccine strategies.
Zdroje
1. LiQ
DuanL
EstesJD
MaZM
RourkeT
2005 Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434 1148 1152
2. MattapallilJJ
DouekDC
HillB
NishimuraY
MartinM
2005 Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434 1093 1097
3. DeeksSG
WalkerBD
2007 Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27 406 416
4. HaynesBF
ShattockRJ
2008 Critical issues in mucosal immunity for HIV-1 vaccine development. Journal of Allergy and Clinical Immunology 122 3 9
5. McMichaelAJ
BorrowP
TomarasGD
GoonetillekeN
HaynesBF
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10 11 23
6. FellayJ
ShiannaKV
GeD
ColomboS
LedergerberB
2007 A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science (Washington, DC, United States) 317 944 947
7. JennesW
VerheydenS
DemanetC
Adje-ToureCA
VuylstekeB
2006 Cutting Edge: Resistance to HIV-1 Infection among African Female Sex Workers Is Associated with Inhibitory KIR in the Absence of Their HLA Ligands. Journal of Immunology 177 6588 6592
8. MartinMP
GaoX
LeeJH
NelsonGW
DetelsR
2002 Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31 429 434
9. FengZ
DubyakGR
LedermanMM
WeinbergA
2006 Cutting edge: human beta defensin 3–a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 177 782 786
10. MuenchJ
StaendkerL
AdermannK
SchulzA
SchindlerM
2007 Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell (Cambridge, MA, United States) 129 263 275
11. MuenchJ
RueckerE
StaendkerL
AdermannK
GoffinetC
2007 Semen-Derived Amyloid Fibrils Drastically Enhance HIV Infection. Cell 131 1059 1071
12. Gasper-SmithN
CrossmanDM
WhitesidesJF
MensaliN
OttingerJS
2008 Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol 82 7700 7710
13. NorrisPJ
PappalardoBL
CusterB
SpottsG
HechtFM
2006 Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 22 757 762
14. StaceyAR
NorrisPJ
QinL
HaygreenEA
TaylorE
2009 Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. Journal of Virology 83 3719 3733
15. FiebigEW
WrightDJ
RawalBD
GarrettPE
SchumacherRT
2003 Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17 1871 1879
16. HusebekkA
PerminH
HusbyG
1986 Serum amyloid protein A (SAA): An indicator of inflammation in AIDS and AIDS-related complex (ARC). Scandinavian Journal of Infectious Diseases 18 389 394
17. UhlarCM
WhiteheadAS
1999 Serum amyloid A, the major vertebrate acute-phase reactant. European Journal of Biochemistry 265 501 523
18. VlasovaMA
MoshkovskiiSA
2006 Molecular interactions of acute phase serum amyloid A: Possible involvement in carcinogenesis. Biochemistry (Moscow) 71 1051 1059
19. MisseD
YsselH
TrabattoniD
ObletC
Lo CaputoS
2007 IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol 178 407 415
20. LiW
SavinovAY
RozanovDV
GolubkovVS
HedayatH
2004 Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha–1-antitrypsin serpin. Cancer Research 64 8657 8665
21. JensenLE
WhiteheadAS
1998 Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 334 489 503
22. DembergT
Robert-GuroffM
2009 Mucosal immunity and protection against HIV/SIV infection: Strategies and challenges for vaccine design. International Reviews of Immunology 28 20 48
23. HeR
ShepardLW
ChenJ
PanZK
YeRD
2006 Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23. J Immunol 177 4072 4079
24. SongC
HsuK
YamenE
YanW
FockJ
2009 Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 207 374 383
25. BlumenthalR
DimitrovDS
2007 Targeting the sticky fingers of HIV-1. Cell (Cambridge, MA, United States) 129 243 245
26. ShapiroL
PottGB
RalstonAH
2001 Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB Journal 15 115 122
27. NakayamaT
SonodaS
UranoT
YamadaT
OkadaM
1993 Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases. Clinical Chemistry 39 293 297
28. Shainkin-KestenbaumR
ZimlichmanS
WinikoffY
1982 Serum amyloid A (SAA) in viral infection: Rubella, measles and subacute sclerosing panencephalitis (SSPE). Clinical and Experimental Immunology 50 503 506
29. YipTTC
ChanJWM
ChoWCS
YipTT
WangZ
2005 Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid A protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clinical Chemistry 51 47 55
30. CaiZ
CaiL
JiangJ
ChangKS
Van Der WesthuyzenDR
2007 Human serum amyloid A protein inhibits hepatitis C virus entry into cells. Journal of Virology 81 6128 6133
31. LavieM
VoissetC
Vu-DacN
ZurawskiV
DuverlieG
2006 Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology 44 1626 1634
32. BristowCL
PatelH
ArnoldRR
2001 Self antigen prognostic for human immunodeficiency virus disease progression. Clinical and Diagnostic Laboratory Immunology 8 937 942
33. HayesVM
Gardiner-GardenM
2003 Are Polymorphic Markers within the alpha-1-Antitrypsin Gene Associated with Risk of Human Immunodeficiency Virus Disease? Journal of Infectious Diseases 188 1205 1208
34. AndersonED
ThomasL
HayflickJS
ThomasG
1993 Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha–1-antitrypsin variant. Journal of Biological Chemistry 268 24887 24891
35. McNeelyTB
ShugarsDC
RosendahlM
TuckerC
EisenbergSP
1997 Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90 1141 1149
36. CongoteLF
2006 The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochemical and Biophysical Research Communications 343 617 622
37. CongoteLF
2007 Serpin A1 and CD91 as host instruments against HIV-1 infection: Are extracellular antiviral peptides acting as intracellular messengers? Virus Research 125 119 134
38. HoltzB
CuniasseP
BoulayA
KannanR
MuchaA
1999 Role of the S1' subsite glutamine 215 in activity and specificity of stromelysin-3 by site-directed mutagenesis. Biochemistry 38 12174 12179
39. LiuZ
ZhouX
ShapiroSD
ShipleyJM
TwiningSS
2000 The serpin alpha-1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102 647 655
40. MastroianniCM
LiuzziGM
2007 Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends in Molecular Medicine 13 449 459
41. MellanenL
LähdevirtaJ
TervahartialaT
MeurmanJH
SorsaT
2006 Matrix metalloproteinase-7, -8, -9, -25, and -26 and CD43, -45, and -68 cell-markers in HIV-infected patients' saliva and gingival tissue. Journal of Oral Pathology and Medicine 35 530 539
42. ZhangZ
WinyardPG
ChidwickK
MurphyG
WardellM
1994 Proteolysis of human native and oxidised alpha–1-proteinase inhibitor by matrilysin and stromelysin. Biochimica et Biophysica Acta - General Subjects 1199 224 228
43. ColeAM
2006 Innate host defense of human vaginal and cervical mucosae.
ShaferWM
Current Topics in Microbiology and Immunology 199 230
44. ColeAM
ColeAL
2008 Antimicrobial polypeptides are key anti-hiv-1 effector molecules of cervicovaginal host defense. American Journal of Reproductive Immunology 59 27 34
45. BurgenerA
BoutilierJ
WachihiC
KimaniJ
CarpenterM
2008 Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. Journal of Proteome Research 7 4446 4454
46. XuD
SuenagaN
EdelmannMJ
FridmanR
MuschelRJ
2008 Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Molecular and Cellular Proteomics 7 2215 2228
47. BatyckaM
InglisNF
CookK
AdamA
Fraser-PittD
2006 Ultra-fast tandem mass spectrometry scanning combined with monolithic column liquid chromatography increases throughput in proteomic analysis. Rapid Communications in Mass Spectrometry 20 2074 2080
48. WesselD
FluggeUI
1984 A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Analytical Biochemistry 138 141 143
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2010 Číslo 5
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Quorum Sensing Inhibition Selects for Virulence and Cooperation in
- The Role of Intestinal Microbiota in the Development and Severity of Chemotherapy-Induced Mucositis
- Susceptibility to Anthrax Lethal Toxin-Induced Rat Death Is Controlled by a Single Chromosome 10 Locus That Includes
- Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species